BiotechTube

Emicizumab

Phase 3Recruiting
0 views this week 0 watching⚡ Active💊Featured in Rare Disease Pipeline Watch
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hemophilia A

Conditions

Hemophilia A

Trial Timeline

Apr 30, 2026 → Jan 29, 2032

NCT ID
NCT07416604

About Emicizumab

Emicizumab is a phase 3 stage product being developed by Chugai Pharmaceutical for Hemophilia A. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07416604. Target conditions include Hemophilia A.

What happened to similar drugs?

20 of 20 similar drugs in Hemophilia A were approved

Approved (20) Terminated (3) Active (0)
✅EmicizumabRocheApproved
✅BenefixPfizerApproved
✅Nonacog alfaPfizerApproved
✅moroctocog alfa (AF-CC) (ReFacto AF)PfizerApproved
✅Recombinant Factor IX CoagulationPfizerApproved
✅Moroctocog alfa(AF-CC)PfizerApproved
✅Factor IX recoveryPfizerApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT07416604Phase 3Recruiting
NCT03020160Phase 3Completed
NCT02795767Phase 3Completed

Competing Products

20 competing products in Hemophilia A

See all competitors
ProductCompanyStageHype Score
EmicizumabChugai PharmaceuticalPhase 3
40
EmicizumabChugai PharmaceuticalPhase 3
40
Emicizumab + rFVIIa + aPCCChugai PharmaceuticalPhase 3
40
Human Coagulation Factor VIIIChugai PharmaceuticalPhase 3
47
Emicizumab + Factor VIII (FVIII)Chugai PharmaceuticalPhase 3
40
EmicizumabRochePhase 3
40
HEMLIBRAJohnson & JohnsonPre-clinical
26
EmicizumabRochePhase 3
40
EmicizumabRocheApproved
47
EmicizumabRochePhase 3
44
SPK-8011QQRochePhase 1/2
39
NXT007RochePhase 1/2
39
Emicizumab InjectionRochePhase 2
35
Bypassing Agents + FVIII ReplacementRochePre-clinical
26
PF-06741086 + PF-06741086 + PF-06741086 + PF-06741086PfizerPhase 2
35
Nonacog Alfa (Genetical Recombination)PfizerPre-clinical
26
Refacto AFPfizerPre-clinical
18
PF-06838435/ fidanacogene elaparvovecPfizerPhase 3
44
ReFacto AFPfizerPhase 3
40
Nonacog alfa + Nonacog alfaPfizerPhase 3
40